HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patricia Fleuranceau-Morel Selected Research

berzosertib

4/2022Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
1/2022A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patricia Fleuranceau-Morel Research Topics

Disease

2Ataxia Telangiectasia (Louis Bar Syndrome)
04/2022 - 01/2022
1Triple Negative Breast Neoplasms
04/2022
1Neoplasms (Cancer)
04/2022
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022
1Systemic Scleroderma (Systemic Sclerosis)
01/2021
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2021
1Knee Osteoarthritis
10/2019
1Osteoarthritis
10/2019
1Arthralgia (Joint Pain)
10/2019
1Infections
01/2019

Drug/Important Bio-Agent (IBA)

2berzosertibIBA
04/2022 - 01/2022
1Cisplatin (Platino)FDA LinkGeneric
04/2022
1PlatinumIBA
04/2022
1GemcitabineFDA Link
01/2022
1VX (EDIM)IBA
01/2022
1Protein Kinase InhibitorsIBA
01/2022
1AbituzumabIBA
01/2021
1Dihydrotachysterol (AT 10)IBA
10/2019
1fibroblast growth factor 18IBA
10/2019
1cyclo(Arg-Pro) (CI 4)IBA
10/2019
1TACI receptor-IgG Fc fragment fusion proteinIBA
01/2019